Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

NCT01243944 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycythemia Vera

Interventions

DRUG: ruxolitinib tablets
OTHER: Best Available Therapy (BAT)

Sponsor

Incyte Corporation

Collaborators

[object Object]